AML with mutated TP53 is characterized by enrichment for gene programs related to T-cell lineage commitment, positive T-cell selection, and T-cell homeostasis, indicating a T-cell-rich environment, as well as for an IFNγ-dominant tumor microenvironment (TME) [76]. The gene discussed is TP53; the disease is neoplasm.